

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Jamp Ipratropium HFA 20 mcg/dose Metered-Dose Aerosol (DIN 02542587) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **June 26, 2025**. The following grouping was removed from the Critical Supply Product List on **May 27, 2025**.

### IPRATROPIUM BROMIDE

#### 20 MCG / DOSE METERED DOSE AEROSOL

00002542587	JAMP IPRATROPIUM HFA	JPC	\$ 0.0563
00002247686	ATROVENT HFA	BOE	\$ 0.1024

Alberta Blue Cross has confirmed that the shortage for Supeudol 5 mg Tablet (DIN 00789739) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **June 30, 2025**. The following grouping was removed from the Critical Supply Product List on **May 30, 2025**.

### OXYCODONE HCL

#### 5 MG TABLET

00000789739	SUPEUDOL	SDZ	\$ 0.1505
00002319977	PMS-OXYCODONE	PMS	\$ 0.1565

Alberta Blue Cross has confirmed that the shortage for Supeudol 10 mg Tablet (DIN 00443948), manufactured by Sandoz Canada Inc., has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **July 21, 2025**. The following grouping was removed from the Critical Supply Product List on **June 20, 2025**.

### OXYCODONE HCL

#### 10 MG TABLET

00000443948	SUPEUDOL	SDZ	\$ 0.2397
00002319985	PMS-OXYCODONE	PMS	\$ 0.2517
00002240131	OXY-IR	PUR	\$ 0.4410

continued next page

*continued from previous page*

### Removal of Temporary Benefit from Alberta Drug Benefit List (ADBL)

Due to the unavailability of Jamp-Cholestyramine 4 g/oral Powder Packet (DIN 02478595) and Olestyr Regular 4 g/oral Powder Packet (DIN 02210320), manufactured by Pharmascience Canada Inc., **Cholestyramine 4 g/oral Powder Packet (US) (PIN 09858335)**, manufactured by Juno Pharma Canada, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Jamp-Cholestyramine 4 g/oral Powder Packet (DIN 02478595) and Olestyr Regular 4 g/oral Powder Packet (DIN 02210320) has been resolved.

**Cholestyramine 4 g/oral Powder Packet (US) (PIN 09858335)** will no longer be considered a temporary benefit for the ADBL after **June 30, 2025**. The above grouping was removed from the Critical Supply Product List on **May 29, 2025**.

---

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

**780-498-8370** (Edmonton and area)

**403-294-4041** (Calgary and area)

**1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area)

**FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

